 Connection
Joshua Barocas to Substance Abuse, Intravenous
This is a "connection" page, showing publications Joshua Barocas has written about Substance Abuse, Intravenous.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
5.667 |
|
|
|
-
Barocas JA, Eftekhari Yazdi G, Savinkina A, Nolen S, Savitzky C, Samet JH, Englander H, Linas BP. Long-term Infective Endocarditis Mortality Associated With Injection Opioid Use in the United States: A Modeling Study. Clin Infect Dis. 2021 12 06; 73(11):e3661-e3669.
Score: 0.717
-
Jawa R, Stein MD, Anderson B, Liebschutz JM, Stewart C, Phillips KT, Barocas JA. Behavioral Risk Factors for HIV Infection in Hospitalized Persons Who Co-use Stimulants and Opioids. AIDS Behav. 2022 Apr; 26(4):1047-1055.
Score: 0.706
-
Barocas JA. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs. Clin Infect Dis. 2021 04 26; 72(8):1401-1403.
Score: 0.687
-
Jawa R, Stein MD, Anderson B, Liebschutz JM, Stewart C, Phillips KT, Barocas JA. Association of skin infections with sharing of injection drug preparation equipment among people who inject drugs. Int J Drug Policy. 2021 08; 94:103198.
Score: 0.682
-
Barocas JA, Morgan JR, Wang J, McLoone D, Wurcel A, Stein MD. Outcomes Associated With Medications for Opioid Use Disorder Among Persons Hospitalized for Infective Endocarditis. Clin Infect Dis. 2021 02 01; 72(3):472-478.
Score: 0.676
-
Schranz A, Barocas JA. Infective Endocarditis in Persons Who Use Drugs: Epidemiology, Current Management, and Emerging Treatments. Infect Dis Clin North Am. 2020 09; 34(3):479-493.
Score: 0.657
-
Barocas JA, Morgan JR, Fiellin DA, Schackman BR, Eftekhari Yazdi G, Stein MD, Freedberg KA, Linas BP. Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids. Int J Drug Policy. 2019 10; 72:160-168.
Score: 0.600
-
Barocas JA, Brennan MB, Hull SJ, Stokes S, Fangman JJ, Westergaard RP. Barriers and facilitators of hepatitis C screening among people who inject drugs: a multi-city, mixed-methods study. Harm Reduct J. 2014 Jan 14; 11:1.
Score: 0.415
-
Wheeler A, Valerio H, Cunningham EB, Martinello M, Barocas JA, Colledge-Frisby S, Treloar C, Amin J, Henderson C, Read P, Matthews GV, Dunlop AJ, Gorton C, Hayllar J, Alavi M, Murray C, Marks P, Silk D, Degenhardt L, Dore GJ, Grebely J. Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. Drug Alcohol Depend. 2022 08 01; 237:109543.
Score: 0.186
-
Grebely J, Collins AB, Artenie AA, Sutherland R, Meyer JP, Barocas JA, Falade-Nwulia O, Cepeda JA, Cunningham EB, Hajarizadeh B, Lafferty L, Lazarus JV, Bonn M, Marshall AD, Treloar C. Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs. Int J Drug Policy. 2021 10; 96:103469.
Score: 0.177
-
Barocas JA, Gai MJ, Amuchi B, Jawa R, Linas BP. Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections. Drug Alcohol Depend. 2020 10 01; 215:108207.
Score: 0.163
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|